Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q2 2021 · 10-Q
Revenue$189.40M$189.40M+103.2% vs Q2 2020 Net Income-$4.70M-$4.70MN/M vs Q2 2020 EPS Diluted-$0.06-$0.06N/M vs Q2 2020 Operating Income-$20,800,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,900,000N/M Margins · derivedOperating margin-11.0%+62.3 pt vs Q2 2020
Net margin-2.5%+57.0 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 4, 2021 · 35 d after period end